FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956048692> ?p ?o ?g. }

• W2956048692 endingPage "2912" @default.
• W2956048692 startingPage "2912" @default.
• W2956048692 abstract "Abstract Recently, the sidedness of the primary tumor (right versus left) has been investigated for its ability to prognosticate and predict outcomes. We evaluated the effect of regorafenib based on KRAS mutation status and the sidedness of the primary tumor in patients with metastatic colorectal cancer (mCRC). We analyzed 135 patients with refractory metastatic colorectal cancer (mCRC) being treated with regorafenib at Samsung Medical Center, between January 2014 and January 2018. Primary tumors originating in the splenic flexure, descending colon, sigmoid colon, rectum, or proximal third of the transverse colon were defined as left-sided CRC (LC). Primary tumors originating in the appendix, cecum, ascending colon, hepatic flexure, or distal two-thirds of the transverse colon were defined as right-sided CRC (RC). Among all 135 patients, 100 (74.1%) had left sided colon cancer and 35 (25.9%) had right-sided colon cancer. No patients achieved a complete response, but four achieved a partial response, revealing a response rate (RR) of 3.0%. Thirty-seven patients had stable disease, yielding a disease control rate (DCR) of 30.4%. There was no difference in RR or DCR according to the location of the primary tumor (LC vs. RC). A significant difference in progression free survival (PFS) with regorafenib was observed between the LC and RC groups (2.6 months; 95% CI, 2.0 to 3.1 vs. 1.9 months; 95% CI, 1.6 to 2.3; P = 0.04, respectively). In a subpopulation with wild type KRAS, PFS with regorafenib was also significantly different between the LC and RC groups (2.9 months; 95% CI, 1.5 to 4.3 vs. 2.1 months; 95% CI, 0.6 to 3.6; P= 0.04). On multivariate analysis, the sidedness of the primary tumor (LC vs. RC) and the number of metastatic sites (≤1 vs. 2&gt;) had a prognostic effect on PFS (P = 0.01 and P = 0.01, respectively). Regorafenib is a current standard treatment for CRC, but treatment outcomes may be improved if regorafenib is administered based on the appropriate biomarker. Citation Format: Sang Eun Yoon, Joon Young Hur, Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park, Seung Tae Kim. The impact of primary tumor sidedness on the effect of regorafenib in refractory metastatic colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2912." @default.
• W2956048692 created "2019-07-12" @default.
• W2956048692 creator A5005933314 @default.
• W2956048692 creator A5015598872 @default.
• W2956048692 creator A5019406140 @default.
• W2956048692 creator A5023718619 @default.
• W2956048692 creator A5026351538 @default.
• W2956048692 creator A5027680603 @default.
• W2956048692 creator A5045587524 @default.
• W2956048692 creator A5057146015 @default.
• W2956048692 creator A5065244228 @default.
• W2956048692 creator A5070300049 @default.
• W2956048692 date "2019-07-01" @default.
• W2956048692 modified "2023-09-27" @default.
• W2956048692 title "Abstract 2912: The impact of primary tumor sidedness on the effect of regorafenib in refractory metastatic colorectal cancer" @default.
• W2956048692 doi "https://doi.org/10.1158/1538-7445.am2019-2912" @default.
• W2956048692 hasPublicationYear "2019" @default.
• W2956048692 type Work @default.
• W2956048692 sameAs 2956048692 @default.
• W2956048692 citedByCount "0" @default.
• W2956048692 crossrefType "journal-article" @default.
• W2956048692 hasAuthorship W2956048692A5005933314 @default.
• W2956048692 hasAuthorship W2956048692A5015598872 @default.
• W2956048692 hasAuthorship W2956048692A5019406140 @default.
• W2956048692 hasAuthorship W2956048692A5023718619 @default.
• W2956048692 hasAuthorship W2956048692A5026351538 @default.
• W2956048692 hasAuthorship W2956048692A5027680603 @default.
• W2956048692 hasAuthorship W2956048692A5045587524 @default.
• W2956048692 hasAuthorship W2956048692A5057146015 @default.
• W2956048692 hasAuthorship W2956048692A5065244228 @default.
• W2956048692 hasAuthorship W2956048692A5070300049 @default.
• W2956048692 hasBestOaLocation W29560486921 @default.
• W2956048692 hasConcept C121332964 @default.
• W2956048692 hasConcept C121608353 @default.
• W2956048692 hasConcept C126322002 @default.
• W2956048692 hasConcept C142424586 @default.
• W2956048692 hasConcept C143998085 @default.
• W2956048692 hasConcept C2776248978 @default.
• W2956048692 hasConcept C2776694085 @default.
• W2956048692 hasConcept C2777807078 @default.
• W2956048692 hasConcept C2778292851 @default.
• W2956048692 hasConcept C2778435480 @default.
• W2956048692 hasConcept C2778822529 @default.
• W2956048692 hasConcept C2779013556 @default.
• W2956048692 hasConcept C2780283643 @default.
• W2956048692 hasConcept C2781074409 @default.
• W2956048692 hasConcept C2781187634 @default.
• W2956048692 hasConcept C3019760618 @default.
• W2956048692 hasConcept C526805850 @default.
• W2956048692 hasConcept C71924100 @default.
• W2956048692 hasConcept C87355193 @default.
• W2956048692 hasConcept C90924648 @default.
• W2956048692 hasConceptScore W2956048692C121332964 @default.
• W2956048692 hasConceptScore W2956048692C121608353 @default.
• W2956048692 hasConceptScore W2956048692C126322002 @default.
• W2956048692 hasConceptScore W2956048692C142424586 @default.
• W2956048692 hasConceptScore W2956048692C143998085 @default.
• W2956048692 hasConceptScore W2956048692C2776248978 @default.
• W2956048692 hasConceptScore W2956048692C2776694085 @default.
• W2956048692 hasConceptScore W2956048692C2777807078 @default.
• W2956048692 hasConceptScore W2956048692C2778292851 @default.
• W2956048692 hasConceptScore W2956048692C2778435480 @default.
• W2956048692 hasConceptScore W2956048692C2778822529 @default.
• W2956048692 hasConceptScore W2956048692C2779013556 @default.
• W2956048692 hasConceptScore W2956048692C2780283643 @default.
• W2956048692 hasConceptScore W2956048692C2781074409 @default.
• W2956048692 hasConceptScore W2956048692C2781187634 @default.
• W2956048692 hasConceptScore W2956048692C3019760618 @default.
• W2956048692 hasConceptScore W2956048692C526805850 @default.
• W2956048692 hasConceptScore W2956048692C71924100 @default.
• W2956048692 hasConceptScore W2956048692C87355193 @default.
• W2956048692 hasConceptScore W2956048692C90924648 @default.
• W2956048692 hasIssue "13_Supplement" @default.
• W2956048692 hasLocation W29560486921 @default.
• W2956048692 hasOpenAccess W2956048692 @default.
• W2956048692 hasPrimaryLocation W29560486921 @default.
• W2956048692 hasRelatedWork W2044658514 @default.
• W2956048692 hasRelatedWork W2092319801 @default.
• W2956048692 hasRelatedWork W2235371377 @default.
• W2956048692 hasRelatedWork W2545643407 @default.
• W2956048692 hasRelatedWork W2547480541 @default.
• W2956048692 hasRelatedWork W2610719567 @default.
• W2956048692 hasRelatedWork W2791459494 @default.
• W2956048692 hasRelatedWork W2923456802 @default.
• W2956048692 hasRelatedWork W2956048692 @default.
• W2956048692 hasRelatedWork W3181087562 @default.
• W2956048692 hasVolume "79" @default.
• W2956048692 isParatext "false" @default.
• W2956048692 isRetracted "false" @default.
• W2956048692 magId "2956048692" @default.
• W2956048692 workType "article" @default.